Melanoma

What are payer desires for efficacy for novel metastatic melanoma agents?
Extensive payer feedback to the latest clinical data of pipeline agents vemurafenib and GSK436/GSK212
What is the current payer management of Yervoy, including tier, reimbursement methodology and restrictions?
What will be the potential payer management of vemurafanib including tier, reimbursement methodology and restrictions?
What is the payer perception of Yervoy’s survival advantage in 1st line setting and immune-related toxicities?
What will be the potential impact of vemurafenib’s market entry on Yervoy’s coverage?
What are payer expectations for pricing of combination agents in metastatic melanoma?
What are payer perceptions and current coverage of the BRAF companion diagnostic test?
What are payer expectations for a fair price of a BRAF companion diagnostic?